Next generation sequencing of blood platelets and PBMCs in early and late stage of melanoma in mice

We report the application of next generation sequencing of blood platelets in an early-early melanoma mice model for screening early cancer biomarkers. By inoculating C57BL/6 mice with different numbers of B16F10 cells, we establish an early-early melanoma model. We find that mice inoculated with lower number of B16F10 cells develop tumors at a later time. Therefore the blood samples collected at day 14 post-injection before the formation of visible tumors are early-early cancer samples. The mRNA profiles of platelets from early-early group are distinct from those of control group and large tumor group. However, the mRNA profiles of PBMCs from early-early group are not so distinct from those of control group and large tumor group. This study provides a proof of concept strategy for future cancer biomarker screening and cancer immunology research. Platelet and PBMC mRNA profiles of different stages of melanomas in C57BL/6 mice